Sign in

Ruben Colman, MD, PhD

@colmanmd.bsky.social
95 followers 83 following 7 posts

Peds GI/IBD Physician Scientist & Director of Intestinal Ultrasound @StanfordPedsGI | #PrecisionMed #ClinPharm #Microbiome | Improving Outcomes ➡️ Innovation

PostsRepliesMedia
Ruben Colman, MD, PhD @colmanmd.bsky.social · 27/06/2026
Exciting #postdoc opportunity in the Precision Therapeutics for IBD - Colman Lab! @stanfordpress.bsky.social - Focus on innovative #Pharmacometrics applications and #microbiome biomarkers - postdocs.stanford.edu/prospective/...
212
Ruben Colman, MD, PhD @colmanmd.bsky.social · 16/02/2026
📣Earlier this month we formally launched the @Stanford Precision Therapeutics for IBD Lab (the Colman Lab)!🧪 - @SMCH_IBD_Celiac @StanfordPedsGI @StanfordChild (1/5)
110
Reposted by Ruben Colman, MD, PhD
Michael Rosen @drmichaelrosen.bsky.social · 14/08/2025
Come practice at the leading edge with an innovative and caring team! Stanford Pediatric GI is hiring clinician educator faculty at all ranks for positions based in the North and East Bay. facultypositions.stanford.edu/en-us/job/49... facultypositions.stanford.edu/en-us/job/49...
001
Reposted by Ruben Colman, MD, PhD
Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · 19/07/2025
ICYMI: New online! The global burden of inflammatory bowel disease: from 2025 to 2045
nature.com
The global burden of inflammatory bowel disease: from 2025 to 2045
Nature Reviews Gastroenterology & Hepatology, Published online: 18 July 2025; doi:10.1038/s41575-025-01097-1The global burden of inflammatory bowel disease (IBD) is shifting as countries transition through four epidemiologic stages. This Perspective explores the global evolution of IBD over the next 20 years and proposes strategies for prevention and health-care innovation.
001
Ruben Colman, MD, PhD @colmanmd.bsky.social · 22/03/2025
Read our #SMCH_IBD_Celiac experience using Intensified Upadacitinib dosing for Adolescent Patients with Acute Severe Ulcerative Colitis. Now in #mdpichildren mdpi.com/3235924 @mdpiopenaccess.bsky.social #PerseusPatel @mosespedsibd.bsky.social @drmichaelrosen.bsky.social #StanfordPedsGI
mdpi.com
012
Reposted by Ruben Colman, MD, PhD
Ben Mullish @bhmullish.bsky.social · 14/12/2024
Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky
academic.oup.com
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV
0257
Reposted by Ruben Colman, MD, PhD
Beatriz Gros @bealoquebea.bsky.social · 21/01/2025
Anthropometric Trajectories in Children Prior to Development of IBD show impaired nutritional status as assessed by weight up to 3 years and by length or height 1 year before a diagnosis of CD and by weight up to 1 year before a diagnosis of UC jamanetwork.com/journals/jam...
jamanetwork.com
Anthropometric Trajectories in Children Prior to Development of IBD
This cohort study assesses the trajectory of anthropometric nutritional status in children before a diagnosis of inflammatory bowel disease (IBD) as well as growth recovery after diagnosis.
011